我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
2
0 进行中
药物批准
98
批准总数
监管机构
1
监管机构数
成立时间
N/A
已完成
100.0%
FDA
Food and Drug Administration
- DelveInsight's 2025 pipeline assessment reveals three key companies are developing novel hemorrhoids treatment therapies, with emerging drugs like EB02, Halo-Lido, and Hydrocortisone Acetate Suppository expected to significantly impact the market. - Citius Pharmaceuticals completed a Phase 2b trial for Halo-Lido (CITI-002) in 2023 and applied for patents in June 2023, positioning the topical formulation as a promising treatment for hemorrhoid relief. - The hemorrhoids treatment market faces growth drivers including rising awareness and increased reported cases, while barriers include lack of specialized healthcare infrastructure and time-consuming treatment procedures.
